Save your place

Sign in to WhoBought

Please try again later.

Ligand Pharmaceuticals Incorporated (LGND) institutional ownership

Market cap$2.6B SectorHealthcare
Funds holding · Q1 2026
339
reported LGND position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
183 buyers · 156 sellers

Ligand Pharmaceuticals Incorporated (LGND) price and institutional activity

Dates

Q1 2026

$0 bought by 183 investors
Invesco Ltd.Next Century Growth Investors LLC +181 more
$0 sold by 156 investors
UBS AMJacobs Levy Equity Management, Inc +154 more
Sign in to see who bought
Bought Sold Totals per quarter; hover a bar for the names.

Ligand Pharmaceuticals Incorporated (LGND) institutional activity · 339

Investor Type Est. change Change Δ Own Date
Invesco Ltd. · Added
Change +307K Δ Own +59.5% Date Q1 2026
Invesco Ltd. Added· Q1 2026 +307K +59.5% Q1 2026
UBS AM · Reduced
Change −151K Date Q1 2026
UBS AM Reduced· Q1 2026 −151K Q1 2026
Jacobs Levy Equity Management, Inc · Reduced
Change −106K Date Q1 2026
Jacobs Levy Equity Management, Inc Reduced· Q1 2026 −106K Q1 2026
Next Century Growth Investors LLC · New
Change +96K Date Q1 2026
Next Century Growth Investors LLC New· Q1 2026 +96K Q1 2026
Massachusetts Financial Services Co · Reduced
Change −95K Date Q1 2026
Massachusetts Financial Services Co Reduced· Q1 2026 −95K Q1 2026
Bessemer Group Inc · Added
Change +84K Date Q1 2026
Bessemer Group Inc Added· Q1 2026 +84K Q1 2026
Nomura Asset Management International Inc. · Reduced
Change −71K Date Q1 2026
Nomura Asset Management International Inc. Reduced· Q1 2026 −71K Q1 2026
Geode · Added
Change +65K Date Q1 2026
Geode Added· Q1 2026 +65K Q1 2026
Goldman Sachs Group Inc · Reduced
Change −48K Date Q1 2026
Goldman Sachs Group Inc Reduced· Q1 2026 −48K Q1 2026
Wells Fargo & Company · Reduced
Change −48K Date Q1 2026
Wells Fargo & Company Reduced· Q1 2026 −48K Q1 2026
Victory Capital Management Inc · Added
Change +47K Date Q1 2026
Victory Capital Management Inc Added· Q1 2026 +47K Q1 2026
Emerald Investment Advisers, LLC · New
Change +44K Date Q1 2026
Emerald Investment Advisers, LLC New· Q1 2026 +44K Q1 2026
F/m Investments LLC · Reduced
Change −44K Date Q1 2026
F/m Investments LLC Reduced· Q1 2026 −44K Q1 2026
D. E. Shaw & Co., Inc. · Added
Change +42K Δ Own +114.6% Date Q1 2026
D. E. Shaw & Co., Inc. Added· Q1 2026 +42K +114.6% Q1 2026
Bank of Montreal · Reduced
Change −40K Date Q1 2026
Bank of Montreal Reduced· Q1 2026 −40K Q1 2026
Data through Q1 2026 · filed Jun 3, 2026
15 of 339

Famous investor activity in Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Incorporated (LGND) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Reardon Andrew · Officer 8 operations −$1.6M
Price $308.99–$317.15 Qty −5K Owned 42K ΔOwn −10.7% Trade date Jul 1, 2026 Filed date Jul 6, 2026
Reardon Andrew Officer 8 operations $308.99–$317.15 −5K −$1.6M 42K −10.7% Jul 1, 2026 Jul 6, 2026
Reardon Andrew · Officer 2 operations 0
Price $52.27 Owned 34K Trade date Jul 1, 2026 Filed date Jul 6, 2026
Reardon Andrew Officer 2 operations $52.27 0 34K Jul 1, 2026 Jul 6, 2026
Reardon Andrew · Officer Other Form 4 events $21K
Price $160.71 Qty 132 Owned 42K ΔOwn +0.3% Trade date Jun 30, 2026 Filed date Jul 6, 2026
Reardon Andrew Officer Other Form 4 events $160.71 132 $21K 42K +0.3% Jun 30, 2026 Jul 6, 2026
Espinoza Octavio · Officer Other Form 4 events $3K
Price $160.71 Qty 17 Owned 28K ΔOwn +0.1% Trade date Jun 30, 2026 Filed date Jul 6, 2026
Espinoza Octavio Officer Other Form 4 events $160.71 17 $3K 28K +0.1% Jun 30, 2026 Jul 6, 2026
Davis Todd C. · Director Other Form 4 events $21K
Price $160.71 Qty 132 Owned 200K ΔOwn +0.1% Trade date Jun 30, 2026 Filed date Jul 6, 2026
Davis Todd C. Director Other Form 4 events $160.71 132 $21K 200K +0.1% Jun 30, 2026 Jul 6, 2026
Sabba Stephen L. · Director Sell −$545K
Price $254.00 Qty −2K Owned 34K Trade date Jun 16, 2026 Filed date Jun 18, 2026
Sabba Stephen L. Director Sell $254.00 −2K −$545K 34K Jun 16, 2026 Jun 18, 2026
Sabba Stephen L. · Director 2 operations 0
Price $66.13 Owned 0 Trade date Jun 16, 2026 Filed date Jun 18, 2026
Sabba Stephen L. Director 2 operations $66.13 0 0 Jun 16, 2026 Jun 18, 2026
Haas Jason · Director 2 operations −$1.7M
Price $255.01–$256.08 Qty −6K Owned 5K Trade date Jun 12, 2026 Filed date Jun 15, 2026
Haas Jason Director 2 operations $255.01–$256.08 −6K −$1.7M 5K Jun 12, 2026 Jun 15, 2026
Haas Jason · Director 4 operations 0
Price $51.56 Owned 6K Trade date Jun 12, 2026 Filed date Jun 15, 2026
Haas Jason Director 4 operations $51.56 0 6K Jun 12, 2026 Jun 15, 2026
Aryeh Jason · Director Sell −$1.1M
Price $250.00 Qty −4K Owned 103K Trade date Jun 11, 2026 Filed date Jun 12, 2026
Aryeh Jason Director Sell $250.00 −4K −$1.1M 103K Jun 11, 2026 Jun 12, 2026
Aryeh Jason · Director Sell −$125K
Price $250.00 Qty −500 Owned 107K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Aryeh Jason Director Sell $250.00 −500 −$125K 107K Jun 10, 2026 Jun 12, 2026
Lamattina John L. · Director 4 operations −$1.2M
Price $247.22–$251.62 Qty −5K Owned 27K Trade date Jun 10, 2026 Filed date Jun 12, 2026
Lamattina John L. Director 4 operations $247.22–$251.62 −5K −$1.2M 27K Jun 10, 2026 Jun 12, 2026
Aryeh Jason · Director 2 operations 4K
Owned 3K Trade date Jun 5, 2026 Filed date Jun 12, 2026
Aryeh Jason Director 2 operations 4K 3K Jun 5, 2026 Jun 12, 2026
Zimmermann Martine · Director Tax withholding or exercise payment (F) -$43K
Price $237.00 Qty -182 Owned 5K Trade date Jun 5, 2026 Filed date Jun 9, 2026
Zimmermann Martine Director Tax withholding or exercise payment (F) $237.00 -182 -$43K 5K Jun 5, 2026 Jun 9, 2026
Zimmermann Martine · Director 2 operations 4K
Owned 3K Trade date Jun 5, 2026 Filed date Jun 9, 2026
Zimmermann Martine Director 2 operations 4K 3K Jun 5, 2026 Jun 9, 2026
15 of 69
15 of 69 Sign in to continue to older insider transactions.

Ligand Pharmaceuticals Incorporated (LGND) activist and large shareholders

What are Schedules 13D and 13G?

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Vanguard Portfolio Management 1.1M
% of shares outstanding 5.6% Filing date May 1, 2026
Vanguard Portfolio Management 1.1M 5.6% May 1, 2026
Vanguard Capital Management 998K
% of shares outstanding 5.0% Filing date May 1, 2026
Vanguard Capital Management 998K 5.0% May 1, 2026
2 of 2

Ligand Pharmaceuticals Incorporated (LGND) ownership FAQ

Who owns LGND?

339 reporting institutions disclosed LGND position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.